Novartis Prexige launch delay?: Novartis anticipates launch of COX-2 inhibitor Prexige (lumiracoxib/COX-189) could be delayed until 2004. "We have here left a range for the launch. It is too early to speculate what the scientific and regulatory environment will be 15 months from now," Clinical R&D Head James Shannon says. "It is possible that we will have a straight 12-month review, and we could get approval at the end of 2003, but we feel it is conservative and gives a better indication, a better guidance, that we place the launch somewhere in 2004." Novartis plans to submit an NDA by year-end; the ongoing TARGET study will not be required for approval (1"The Pink Sheet" Nov. 12, 2001, p. 32)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.